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Abstract
Background Hypercholesterolaemia is an important mod-
ifiable risk factor for cardiovascular disease (CVD) which
requires monitoring and management at a population level.
Aims This study aims to describe the distribution of serum
cholesterol in a community living population of older
adults in Ireland and to examine the awareness, treatment
and control of hypercholesterolaemia according to CVD
risk status.
Method This is a cross-sectional study in a nationally
representative sample of adults aged 50–79 years
(n = 5287). Hypercholesterolaemia was defined as low-
density lipoprotein cholesterol (LDL-C) in excess of the
recommended CVD risk category target and/or on lipid-
lowering medication.
Results This study reports a mean total cholesterol (TC) of
5.1 mmol/L (95% CI 5.0–5.1 mmol/L) and a mean LDL-C
of 2.9 mmol/L (95% CI 2.8–2.9 mmol/L) in those aged
50–79 years. In a subgroup aged 50–64 years, 73% (95%
CI 71.5–74.5%) were hypercholesterolaemic. LDL-C was
controlled to the guideline target in 57% of those with
CVD and 49% of those with diabetes. Lack of awareness of
hypercholesterolaemia was high across the remainder of
the population.
Conclusion Despite a substantial reduction in population
mean TC from a high of 6.0 mmol/L in the 1980s to
5.1 mmol/L, this study reports a failure to control hyper-
cholesterolaemia to recommended risk-stratified targets in
the Irish adult population. Recommendations for policy
include continued monitoring of those at highest risk and
CVD risk assessment in those perceived to be at low risk in
order to inform shared decision making in relation to
lifestyle modification and medication management.
Keywords Hypercholesterolaemia  Dyslipidaemia  Older
adults  Cardiovascular disease  CVD risk
Introduction
Although cardiovascular disease is the leading cause of
mortality globally [1] and the leading cause of mortality in
Ireland accounting for almost a third of all deaths [2],
nonetheless, between 1985 and 2006, coronary heart dis-
ease mortality decreased by 68% in men and 69% in
women [3]. Almost half of the reduction was attributed to
improvements in risk factor levels; 24% was attributed to a
reduction in population cholesterol levels [3].
Raised serum cholesterol is an important modifiable risk
factor for the development of cardiovascular disease. A
reduction in total cholesterol of 1 mmol/L is associatedwith a
33% reduction in ischaemic heart disease mortality in those
aged 50–69 years and a reduction of 17% in those aged
70–89 years [4]. At a population level, total cholesterol (TC),
low-density lipoprotein cholesterol (LDL-C) and high-density
lipoprotein cholesterol (HDL-C) are assessed to characterise
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abnormal cholesterol levels [5, 6].GloballymeanTCdeclined
by 0.1 mmol/L between 1980 and 2008 with higher income
regions including western Europe declining by 0.2 mmol/L
for both sexes [7]. Despite an overall downward trend, a
reversal of this trend at population level has recently been
observed in Sweden between 2008 and 2010 [8].
Reliable population based data are required in order to
monitor the management of hypercholesterolaemia, pro-
vide evidence for policy and evaluate cardiovascular dis-
ease programmes at a national level. The Irish
Longitudinal Study on Ageing (TILDA) provides the
opportunity to bridge this information gap.
Clinical guidelines on cholesterol reduction are based on
overall CVD risk and not on the absolute level of choles-
terol with targets identified according to absolute risk sta-
tus. The aim of this study is to document the distribution of
serum cholesterol in a community living population of
older adults aged 50–79 years in Ireland and apply clinical
guideline targets [9] to examine the awareness, treatment
and control of hypercholesterolaemia in a subgroup aged
50–64 years according to their absolute risk of CVD.
Methods
Sample design
The Irish Longitudinal Study on Ageing (TILDA) is an
ongoing prospective cohort study representative of com-
munity living adults in Ireland aged 50 years and older.
The sample was recruited based on a national directory of
residential addresses using the RANSAM system [10].
Participants were invited to take part in a home-based
interview followed by a health assessment conducted by a
research nurse in a designated centre or at home. The study
uses cross-sectional data from the baseline wave (October
2009 to July 2011). Analyses are based on those aged
50–79 years at baseline who participated in the health
assessment and provided a blood sample (n = 5287).
European Society of Cardiology guidelines and CVD
risk
The European Society of Cardiology guidelines current
during the data collection period recommended TC and
LDL-C targets based on absolute CVD risk [9]. The Sys-
tematic COronary Risk Estimation (SCORE) based on a
European cohort, estimates the 10-year risk of first fatal
atherosclerotic event in asymptomatic individuals up to the
age of 64 years based on five risk factors: age, sex, systolic
blood pressure, total cholesterol and smoking status [11].
Ireland was classified as a ‘‘low risk’’ country based on
CVD and diabetes mortality in 2008, therefore the
corresponding risk equations were applied to the TILDA
data. Individuals in the sub group (50–64 years) already
known to be at high risk for CVD i.e. those with known
CVD or diabetes were not classified using SCORE. The
remaining participants were classified into one of four
CVD risk categories; Very high risk (SCORE C10%), High
risk (SCORE C5 and\10%), moderate risk (SCORE C1
and\5%) and low risk (SCORE\1%).
Lipid measurements
Non fasting venous blood was drawn during the health
assessment. The TILDA protocol for blood sample col-
lection, processing and storage has been described previ-
ously [12]. Briefly, 5 mL of fresh whole blood was
collected in Lithium heparin coated tubes and transported
to a central processing laboratory in temperature-controlled
shipping boxes which maintained the samples at 2–8 C for
up to 48 h. Plasma samples were then isolated in 1 ml
aliquots and placed at 2–8 C for up to 72 h prior to lipid
profile analysis. Lipid concentrations were analysed using
Siemans Dimension Xpand chemistry analyser.
Total cholesterol was measured using a single reagent,
endpoint reaction method that is specific for cholesterol. The
assay is optimised against the Centres for Disease Control and
Prevention (CDC) and the National Institute of Standards and
Technology (NIST) reference methods. The method is stan-
dardised against the Abell/Kendall method and isotope dilu-
tion/mass spectrometry. The assay met the 1992 National
Institutes of Health goal for precision and bias. LDL-C was
calculated using the Friedewald formula. LDL-C is underes-
timated at higher triglyceride concentrations, therefore LDL-
C was only calculated on participants with triglyceride values
\4.0 mmol/L [13]. A direct determination of high-density
lipoprotein cholesterol (HDL-C) was performed using PEG-
modified enzymes and dextran sulphate. The Roche HDL-C
assay meets the 1998 National Institutes of Health/National
Cholesterol Program (NCEP) for acceptable perfor-
mance. The results of this method correlate with those
obtained by precipitation-based methods and also by ultra-
centrifugation. The method has been standardised against the
designated CDC reference method. The standardisation
meets the requirements of the ‘‘HDL-Cholesterol Method
Evaluation Protocol for Manufacturers’’ of the US National
Reference System for Cholesterol, CRMLN (Cholesterol
Reference Method Laboratory Network), 1994.
In the subgroup aged 50–64, hypercholesterolaemia was
defined as a LDL-C in excess of the risk category target as
outlined in the guidelines (Table 3) and/or on lipid-low-
ering medication. Control of hypercholesterolaemia was
defined as LDL-C below the guideline target in conjunction
with the use of lipid-lowering medication.
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Measurements
Demographic and social characteristics considered in this
analysis include age, sex and highest educational attain-
ment (primary, secondary and tertiary). Lipid-lowering
medication use was recorded during the home interview.
Medication was classified according to the WHO anatom-
ical therapeutic chemical classification system (ATC), all
medications coded C10 were included. Good agreement
has been demonstrated in this cohort between lipid-low-
ering medication recorded at interview and pharmacy dis-
pensing records (k = 0.73, 95% CI 0.69–0.77) [14].
Cardiovascular disease (angina, myocardial infarction,
heart failure, stroke, transient ischaemic attack, stent/vas-
cular surgery), diabetes and high cholesterol were self-re-
ported based on ever having a doctor’s diagnosis of these
conditions. Respondents were also asked if they had ever
had a blood test for cholesterol.
Physical activity was self-assessed using the Interna-
tional Physical Activity Questionnaire (IPAQ) short form
and categorised into low, moderate or high levels of
physical activity [15]. Blood pressure was measured twice
during the health assessment and the mean systolic and
diastolic blood pressure recorded. Smoking status was self-
reported during the home interview. Three mutually
exclusive medical insurance categories were used, these
include those with (a) a medical card which provides free
access to primary care and subsidised medication (b) pri-
vate health insurance only and (c) no health insurance.
Statistical analysis
Descriptive statistics are presented at percentages, means
and standard deviations. Statistical significance was cal-
culated using t tests for continuous variables and Chi-
squared tests for categorical variables and set at p\ 0.05.
Statistical weights were applied to the sample to adjust for
selection bias and non-response to the health assessment
component of the survey. Individual weights were cali-
brated against the age, sex and educational profile of the
Irish population sourced from the Quarterly National
Household Survey 2010 compiled by the Irish Central
Statistics Office. The subgroup analysis is unweighted.
Statistical analysis was performed using the TILDA wave 1
data file v1-7-8 and statistical software Stata/MP V.12.1
Results
The household response rate to the baseline TILDA survey
was 62%. Of the 8175 adults who participated in the
TILDA study, 7537 were aged between 50 and 79 years.
Of these, 70.1% (n = 5287) took part in the health
assessment, had complete risk factor data available and
were included in the analysis. The included participants
were younger; more highly educated and displayed more
favourable cardiovascular risk characteristics when com-
pared to those not included in the analysis e.g. smoking
(Table 1).
Total cholesterol, LDL cholesterol and HDL
cholesterol
The weighted mean TC, LDL-C and HDL-C in the popu-
lation aged 50–79 years are detailed in Table 2. Figure 1
graphically depicts the weighted mean TC, LDL-C and
HDL-C according to sex and 5 year age group and shows a
decline with advancing years more marked in men than in
women for TC and LDL-C, whereas HDL-C remained
unchanged with age.
LLM was used by 33.9% (95% CI 32.3–35.4%) of the
sample. This proportion varied significantly across medical
insurance categories. A higher proportion of those with a
medical card (42.1%, 95% CI 39.7–44.5%) were on LLM
compared to 28.4% (95% CI 26.3–30.4%) of those with
private insurance only and 22.5% (95% CI 18.8–26.1%) of
those with no medical insurance. This difference persisted
after adjustment for age, sex and educational status. In
those not taking LLM, the weighted mean TC was
5.3 mmol/L (95% CI 5.3–5.4), 5.1 mmol/L (95% CI
5.1–5.2) in men and 5.5 mmol/L (95% CI 5.5–5.6) in
women (Table 2). In this group (not on LLM) the weighted
mean TC and LDL-C peaked in men aged 55–59 years and
in women aged 60–64 years (Fig. 2).
A high proportion of participants 88.9% (95% CI
87.8–89.9%) reported ever having a blood test for choles-
terol. This proportion varied significantly with age from
82.6% (95% CI 80.1–85.1%) in the 50-54 year age group
to 94.4% (95% CI 91.8–96.9%) in the 75–79 year age
group. Equal proportions of men and women self-reported
a blood test for cholesterol. In total, 41.1% (95% CI
39.6–42.7%) reported ever having a doctor’s diagnosis of
high cholesterol.
Almost half of the population aged 50–79 years (44.8%,
95% CI 43.3–46.3%) had a TC\5 mmol/L and just over
half (51.3%, 95% CI 49.8–52.8%) had an LDL-C
\3 mmol/L. Only 22.3% (95% CI 21.1–23.5%) had a TC
\5 mmol/L and were not on LLM, and 26.6% (95% CI
25.3–27.9%) had an LDL-C\3 mmol/L and were not on
LLM.
Hypercholesterolaemia according to CVD risk
status
A subgroup analysis was conducted on those aged
50–64 years, in whom absolute risk based on SCORE or
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morbidity status could reliably be calculated (n = 3227).
This population were categorised into six groups: known
CVD 4.8% (n = 155), know diabetes 4.2% (n = 135),
very high SCORE risk 0.6% (n = 20), high SCORE risk
3.4% (n = 109), moderate SCORE risk 49.2%
(n = 1587) and low SCORE risk 37.8% (n = 1221). The
Table 1 Characteristics of TILDA participants (TILDA wave 1, 50–79 years)
All eligible participants
(n = 7537)
Included in the analysis
(n = 5287)
Excluded from the analysis
(n = 2250)
p value
Age mean (SD) 62.1 (8.1) 61.7 (7.9) 63.2 (8.5) \0.001
Male sex (%) 46.0 46.5 45.0 0.236
Education
Primary 28.5 24.1 38.8
Secondary 40.9 41.8 38.6
Tertiary 30.5 33.9 22.4 \0.001
Smoker 19.0 16.1 25.7 \0.001
Physical activity
Low 30.1 28.6 33.8
Moderate 34.7 35.3 33.3
High 35.0 36.0 32.7 \0.001
Health insurance
No cover 11.1 11.0 11.5
Private health
insurance
43.2 48.5 30.7
Medical card 45.6 40.4 57.7 \0.001
Known CVD 10.6 10.0 12.2 0.004
Known diabetes 7.4 6.9 8.8 0.003
Lipid-lowering
medication
32.6 33.9 29.7 0.001
Included in the analysis: participants were included in the analysis if they took part in the home interview and the health assessment and provided
full risk factor data including providing a blood sample
Statistical significance was calculated using t test for continuous variables and Chi-square test for categorical variables
CVD cardiovascular disease, TILDA The Irish Longitudinal Study on Ageing
Table 2 Weighted total
cholesterol, low-density
lipoprotein cholesterol and
high-density lipoprotein
cholesterol according to sex and
lipid-lowering treatment status
(TILDA wave 1, 50–79 years)
On LLM No LLM All n
Mean (95% CI) Mean (95% CI) Mean (95% CI)
Total cholesterol, mmol/L
Male 4.3 (4.2–4.4) 5.1 (5.1–5.2) 4.8 (4.8–4.9) 2459
Female 4.8 (4.8–4.9) 5.5 (5.5–5.6) 5.3 (5.3–5.4) 2828
Total 4.5 (4.5–4.6) 5.3 (5.3–5.4) 5.1 (5.0–5.1) 5287
LDL cholesterol, mmol/L
Male 2.2 (2.1–2.3) 3.0 (3.0–3.1) 2.7 (2.7–2.8) 2316
Female 2.5 (2.5–2.6) 3.2 (3.1–3.2) 3.0 (2.9–3.0) 2753
Total 2.4 (2.3–2.4) 3.1 (3.1–3.2) 2.9 (2.8–2.9) 5069
HDL cholesterol, mmol/L
Male 1.3 (1.2–1.3) 1.3 (1.3–1.4) 1.3 (1.3–1.4) 2459
Female 1.6 (1.5–1.6) 1.7 (1.6–1.7) 1.6 (1.6–1.7) 2828
Total 1.4 (1.4–1.4) 1.5 (1.5–1.5) 1.5 (1.5–1.5) 5287
LLM lipid-lowering medication, LDL cholesterol low-density lipoprotein cholesterol, HDL cholesterol
high-density lipoprotein cholesterol, CI confidence interval, TILDA The Irish Longitudinal Study on
Ageing
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very high SCORE risk group and the high SCORE risk
group were combined into a single group (n = 129) due
to the small number in the very high risk group and the
identical LDL-C targets for these two groups in the
clinical guidelines.
Targets for LDL-C according to CVD risk are identified
in Table 3, column one [9]. Hypercholesterolaemia
prevalence (LDL-C above CVD risk category target and/or
on LLM) was 73% (95% CI 71.5–74.5%) (n = 2357)
overall with the prevalence ranging from 66.6% (95% CI
Fig. 1 Weighted mean total
cholesterol, mean LDL
cholesterol and mean HDL
cholesterol according to sex and
age group (TILDA wave 1,
50–79 years, n = 5287)
Fig. 2 Weighted mean total
cholesterol, mean LDL
cholesterol according to sex and
age group and lipid-lowering
medication status (TILDA wave
1, 50–79 years, n = 5287)
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64.0–69.3%) in the low risk group to 90.9% (95% CI
86.4–95.5%) in those with known CVD.
Examination of those with hypercholesterolaemia
(n = 2357) revealed a varied picture in relation to aware-
ness, treatment and control of LDL-C depending on the
absolute level of CVD risk of individual participants
(Fig. 3). Over half of those with known CVD and close to
half of those with known diabetes (49%) were treated and
controlled to the recommended LDL-C target level. This
contrasts with the small proportion (5%) treated and con-
trolled to target in the very high/high SCORE risk group.
Lack of awareness of hypercholesterolaemia was lowest in
those with existing disease (CVD and Diabetes) and high
across all SCORE risk groups.
Discussion
The study reports a weighted mean TC of 5.1, 4.8 mmol/L
in men and 5.3 mmol/L in women and a weighted mean
LDL-C of 2.9, 2.7 mmol/L in men and 3.0 mmol/L in
women in a nationally representative sample of adults aged
50–79 years in the Irish population during the period
2009–2011. One-third of adults in the age group were on
lipid-lowering medication. In a subgroup aged
50–64 years, the prevalence of hypercholesterolaemia was
73%. Despite European and National policy recommen-
dations and guidelines regarding the risks associated with
high cholesterol [9, 16], control of LDL-C in those at
highest risk for a CVD event is lower than expected with
57% of those with known CVD and 49% of diabetics
achieving guideline targets. Lack of awareness of hyperc-
holesterolaemia was high across all primary prevention risk
groups.
These results compare with findings from a nationally
representative cohort of non-institutionalised adults aged
20 years and older in the National Health and Nutrition
Examination Surveys (NHANES) in the United States
which found an overall TC of 196 mg/dL (equivalent to
5.0 mmol/L) and LDL-C of 116 mg/dL (equivalent to
3.0 mmol/L) during the time period 2007–2010 [17]. The
Health Survey for England 2011 conducted in a community
living sample of adults aged 16 years and older found a
mean TC of 5.1 mmol/L in men and 5.2 mmol/L in women
[18]. Differences in the age profile of participants in other
studies creates difficulty in making direct comparisons,
however, certain patterns in the data are similar to those
found elsewhere. Women had higher cholesterol levels
than men at all ages beyond 50 years in our study. This is
similar to other studies of younger cohorts which found
that up to the age of 50 years men had higher cholesterol
levels than women, however, once over the age of 50 years
women have higher cholesterol levels [19]. The finding that
cholesterol levels peak higher and later in women com-
pared to men is consistent with findings from representa-
tive surveys of the French population in 2006/2007 [20]
and the Health Survey for England 2011 [19]. This unique
rise in cholesterol in peri-menopausal women is also doc-
umented in the Study of Women’s Health across the Nation
(SWAN) in the United States which highlights the impor-
tance of monitoring lipids in older women [21].
Previously in Ireland, the Kilkenny health project con-
ducted TC examinations at baseline on an intervention and
reference group (aged 35–64 years) in 1985–1986. Mean
total cholesterol in men was 6.0 mmol/L in the intervention
and in the reference group and 6.0 mmol/L in women in
the intervention group and 5.9 mmol/L in the reference
group [22]. While our study examines TC in an older
cohort (50–79 years) it identifies a substantial decline in
TC of approximately 0.9 mmol/L in the population over a
25 year period and may reflect a survivorship effect. This
decline exceeds the 0.2 mmol/L decline in TC per decade
in the European region as outlined by Farzadfar et al. [7]
and is similar to results from the northern Sweden
Table 3 Hypercholesterolaemia prevalence according to CVD risk status in adults aged 50–64 years (TILDA wave 1)
Target LDL-Ca LDL-C Hypercholesterolaemia Total
mmol/L Mean (SD) % (95% CI) n
Known CVD \2.5 2.3 (1.0) 90.9 (86.4–95.5) 155
Known diabetes \2.5 2.4 (1.0) 86.6 (80.8–92.4) 135
Very high risk and high risk \2.5 3.4 (1.0) 89.9 (84.6–95.1) 129
Moderate risk \3.0 3.1 (0.9) 73.6 (71.4–75.8) 1587
Low risk \3.0 3.0 (0.8) 66.6 (64.0–69.3) 1221
Total – 3.0 (0.9) 73.0 (71.5–74.5) 3227
Very high and high risk = SCORE C5%, Moderate risk = SCORE C1 and\5%, Low risk = SCORE\1%
a 2007 Guidelines [9]
CVD cardiovascular disease, LDL-C low-density lipoprotein cholesterol, SD standard deviation, CI confidence interval, TILDA The Irish
Longitudinal Study on Ageing, Hypercholesterolaemia LDL-C above target for risk group and/or on lipid-lowering medication
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MONICA study between 1994 and 2014, where cholesterol
levels decreased by 0.7 mmol/L in the 20 year period [23].
Previous research on a sample of 1207 adults aged 45 years
and older taken from a nationally representative sample of
adults in Ireland found that 18% of the population had a TC
\5 mmol/L and were not on lipid-lowering medication
[24]. Our study found an increase in this proportion to
22%. This may be partly due to our larger sample size,
slightly older age profile or an improvement in dietary and
lifestyle factors in the population during the intervening
time period.
The use of cholesterol-lowering medication in this
cohort (33%) was slightly higher than that reported by the
National Health and Nutrition Examination Survey
(NHANES) during 2011–2012 when 28% of adults aged
40 years and older were reported using prescription
cholesterol-lowering medication in the previous 30 days
[25].
The findings in the subgroup aged 50–64 years present
an opportunity to examine interventions aimed at lowering
cholesterol according to an individual’s CVD risk profile.
In individuals at high risk of future CVD events i.e. those
with existing CVD or diabetes, opportunities are being
missed to achieve LDL-C control as recommended in
clinical guidelines. These findings corroborate those found
in an observational cohort of Irish patients during the same
time period which found persistent dyslipidaemia despite
statin therapy [26]. Our findings also reveal a low level of
treatment and control and lack of awareness in those
classified as very high risk (SCORE C10%) or high risk
(SCORE C5 and\10%). Providing risk information has
been shown to change high risk patients perception of risk
and physician’s prescribing habits [27] yet recent research
from Ireland found that only a third of general practitioners
(GPs) frequently use a CVD risk assessment tool in prac-
tice [28]. Our data is limited in that we collected infor-
mation on current medication use and therefore cannot
ascertain prescription of lipid-lowering medication and the
extent to which non adherence to treatment is a feature of
our data. Individuals at lower absolute CVD risk are
required to weigh up the smaller benefits to them individ-
ually of taking medication and the adoption of lifestyle
modification in consultation with their general practitioner
(GP). In one UK study following the widening of the risk
threshold for offering statin therapy one in four patients
took up the opportunity to discuss starting statins with their
GP and only one in ten chose to start a statin [29]. Poor
adherence to statins is reported in primary prevention
Fig. 3 Awareness treatment
and control of
hypercholesterolaemia
according to cardiovascular
disease risk status (TILDA
wave 1, 50–64 years)
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populations with low perceived risk a strong predictor of
poor adherence and many displaying a preference for
dietary control [30]. Our findings reveal a lack of aware-
ness of hypercholesterolaemia in the primary prevention
population including those at low, moderate and high
absolute risk. The largest number of future cases of CVD
will arise in the moderate risk group due to its relative size.
Our findings suggest that opportunities to promote dietary
and lifestyle modification at a population level to reduce
future CVD are being missed.
The strengths of this study include the large nationally
representative sample which allows us to generalise our
findings to the older adult population in Ireland. Additional
strengths include the use of standardised protocols for the
interviews, health assessments and laboratory methods.
The TC and LDL-C levels reported may underestimate the
cholesterol profile in this population as those included in
the analysis had more favourable risk profiles than
respondents who did not take part in the health assessment
and thus were excluded from the analysis. This selection
bias was addressed at the design stage by the inclusion of
home and health centre based assessments and at the
analysis stage by the utilisation of calibration weights.
Information on cholesterol testing and awareness of
hypercholesterolaemia was based on self-report which may
be subject to misclassification. In this study we used the
SCORE risk assessment tool and associated guideline
LDL-C target thresholds. However, a large number of CVD
risk assessment tools are in use in primary care [27, 31].
While most recommend prediction models based on simple
risk factor data for decision making or further investigation
and management, there is no consensus on the strategy for
screening, recommended target populations, screening tests
or treatment thresholds [31]. We acknowledge the uncer-
tainty this creates in using a single risk assessment tool in
our analysis.
Our findings show a decrease in TC and LDL-C in line
with global trends which are likely driven by improve-
ments in diet and pharmacological interventions which
reduce cholesterol. Despite these improved results at a
population level, our analysis of the levels of awareness,
treatment and control of hypercholesterolaemia within
CVD risk categories demonstrates an ongoing need for
targeted interventions to reduce LDL-C especially in those
at highest risk of CVD in the older Irish population.
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